Biocytogen Partner IDEAYA Receives FDA Clearance for Phase 1 Trial of IDE034
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Should l Buy 02315?
Source: Newsfilter
- Clinical Trial Approval: Biocytogen's partner IDEAYA Biosciences has received FDA clearance to initiate a Phase 1 clinical trial for IDE034, expected to begin patient enrollment in Q1 2026, marking a significant milestone that could provide new therapies for various tumor patients.
- Technical Validation: IDE034, as a first-in-class B7H3/PTK7 bispecific antibody-drug conjugate, showcases Biocytogen's technical capabilities in bispecific ADC discovery and development, further solidifying its competitive position in the biopharmaceutical sector.
- Clinical Potential: Preclinical studies have demonstrated that IDE034 monotherapy induces deep and durable tumor regressions in multiple B7H3/PTK7-positive tumor models, indicating strong anti-tumor activity, with future plans to explore combination strategies with PARG inhibitor IDE161 to enhance efficacy.
- Market Outlook: The co-expression rates of B7H3 and PTK7 in lung, colorectal, and head and neck cancers are approximately 30%, 46%, and 27%, respectively, indicating the broad clinical application potential of IDE034, while Biocytogen will continue to provide high-quality antibodies through RenBiologics to support clinical translation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy 02315?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on 02315
Wall Street analysts forecast 02315 stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 53.500
Low
Averages
High
Current: 53.500
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HSI Rises 44 Points in Half-Day Trading as SMIC Jumps Over 3% and BIOCYTOGEN-B Surges 20%
Market Performance: On December 24, the HSI rose by 44 points (0.17%) to close at 25,818, with a total market turnover of $92.524 billion. The HSCEI and HSTECH also saw slight increases.
US Tariff Extension: The US has extended the deadline for additional tariffs on Chinese chips to June 2027, impacting market dynamics.
Stock Movements: SMIC's share price increased by 3.1% after raising production prices, while Cathay Pacific's stock fell 0.5% due to leadership changes.
Notable Stock Changes: Biocytogen-B surged 22.2% after being added to the Southbound Stock Connect, while Playmates Toys dropped over 14% due to a licensing agreement expiration.
See More
BIOCYTOGEN-B Surges Over 20% Following Inclusion in Southbound Stock Connect
Stock Performance: BIOCYTOGEN-B (02315.HK) surged by 22.79% to HKD35.24, with a trading volume of 9.837 million shares worth HKD327 million.
Market Inclusion: The Shenzhen and Shanghai Stock Exchanges announced that BIOCYTOGEN-B is now eligible for the Southbound Stock Connect, effective today (24th).
See More
BIOCYTOGEN-B Now Included in Securities Eligible for Southbound Stock Connect, Effective Immediately
Stock Addition Announcement: The Shenzhen Stock Exchange has added BIOCYTOGEN-B (02315.HK) to the list of securities eligible for the Southbound Stock Connect, effective today, October 24th.
Stock Performance: Following the announcement, BIOCYTOGEN-B experienced a significant increase in its stock price, rising by 6.320, which represents a 22.021% gain.
See More
Biocytogen Lists on STAR Market, Opening Price Surges 117% to 58 RMB
- Listing Milestone: Biocytogen successfully lists on the STAR Market with an IPO price of 26.68 RMB, opening at 58 RMB, a 117% increase, resulting in a market cap exceeding 25.9 billion RMB, marking its position as the first “H+A” dual-listed global drug innovator.
- Platform Advantage: The company’s RenMice® platforms enable the discovery of fully human monoclonal antibodies across over 1,000 druggable targets, having advanced more than 40 PCC-to-IND stage assets, showcasing its robust capabilities in antibody drug development.
- Global Collaborations: Biocytogen has established over 280 global discovery partnerships and successfully out-licensed more than 10 clinical or near-clinical programs, further solidifying its leadership in the global biotechnology sector.
- Strategic Expansion: This listing will facilitate Biocytogen's global expansion and platform commercialization, leveraging the synergies of its “H+A” dual-listing structure to deepen collaborations with international partners and drive the discovery of novel therapies to benefit global healthcare.
See More
Biocytogen Lists on Shanghai STAR Market, Opens 117% Higher
- Listing Milestone: Biocytogen successfully listed on the Shanghai STAR Market with an IPO price of 26.68 RMB per share, opening at 58 RMB, which represents a 117% increase over the offering price and a market capitalization exceeding 25.9 billion RMB, marking its status as the first “H+A” dual-listed global drug innovator.
- Platform Advantage: The company leverages its RenMice® platforms to support the discovery of fully human monoclonal antibodies across over 1,000 druggable targets, having advanced more than 40 assets from PCC to IND stage, showcasing its leadership in antibody drug development.
- Global Collaborations: Biocytogen has established over 280 global discovery partnerships, including more than 10 successful out-licensing clinical or near-clinical programs, further solidifying its influence in the international market.
- Strategic Expansion: This listing will facilitate Biocytogen's global expansion and platform commercialization, leveraging the synergies of its “H+A” dual-listing structure to deepen collaborations with international partners and drive the discovery of novel therapies to benefit global healthcare.
See More
Biocytogen's Partner IDEAYA Receives FDA Clearance for Phase 1 Trial of IDE034
- Clinical Trial Approval: IDEAYA has received FDA clearance to initiate a Phase 1 clinical trial for IDE034, with patient enrollment expected to begin in Q1 2026, marking a significant milestone for Biocytogen in the development of bispecific antibody-drug conjugates (ADCs).
- Technical Validation: IDE034, a bispecific B7H3/PTK7 TOP1 ADC independently developed by Biocytogen, will drive subsequent clinical development following its licensing, showcasing Biocytogen's technical capabilities in bispecific ADC discovery and development.
- Anti-Tumor Activity: Preclinical studies have demonstrated that IDE034 monotherapy induces deep and durable tumor regressions in multiple B7H3/PTK7-positive tumor models, indicating its strong anti-tumor activity and potential to offer new therapeutic options for patients.
- Combination Strategy Exploration: IDEAYA plans to explore combination strategies with its PARG inhibitor IDE161 to enhance response durability and intends to present additional preclinical data supporting the combination rationale at a major medical conference in H1 2026.
See More
HSI Rises 44 Points in Half-Day Trading as SMIC Jumps Over 3% and BIOCYTOGEN-B Surges 20%
Market Performance: On December 24, the HSI rose by 44 points (0.17%) to close at 25,818, with a total market turnover of $92.524 billion. The HSCEI and HSTECH also saw slight increases.
US Tariff Extension: The US has extended the deadline for additional tariffs on Chinese chips to June 2027, impacting market dynamics.
Stock Movements: SMIC's share price increased by 3.1% after raising production prices, while Cathay Pacific's stock fell 0.5% due to leadership changes.
Notable Stock Changes: Biocytogen-B surged 22.2% after being added to the Southbound Stock Connect, while Playmates Toys dropped over 14% due to a licensing agreement expiration.
See More
BIOCYTOGEN-B Surges Over 20% Following Inclusion in Southbound Stock Connect
Stock Performance: BIOCYTOGEN-B (02315.HK) surged by 22.79% to HKD35.24, with a trading volume of 9.837 million shares worth HKD327 million.
Market Inclusion: The Shenzhen and Shanghai Stock Exchanges announced that BIOCYTOGEN-B is now eligible for the Southbound Stock Connect, effective today (24th).
See More
BIOCYTOGEN-B Now Included in Securities Eligible for Southbound Stock Connect, Effective Immediately
Stock Addition Announcement: The Shenzhen Stock Exchange has added BIOCYTOGEN-B (02315.HK) to the list of securities eligible for the Southbound Stock Connect, effective today, October 24th.
Stock Performance: Following the announcement, BIOCYTOGEN-B experienced a significant increase in its stock price, rising by 6.320, which represents a 22.021% gain.
See More
Biocytogen Lists on STAR Market, Opening Price Surges 117% to 58 RMB
- Listing Milestone: Biocytogen successfully lists on the STAR Market with an IPO price of 26.68 RMB, opening at 58 RMB, a 117% increase, resulting in a market cap exceeding 25.9 billion RMB, marking its position as the first “H+A” dual-listed global drug innovator.
- Platform Advantage: The company’s RenMice® platforms enable the discovery of fully human monoclonal antibodies across over 1,000 druggable targets, having advanced more than 40 PCC-to-IND stage assets, showcasing its robust capabilities in antibody drug development.
- Global Collaborations: Biocytogen has established over 280 global discovery partnerships and successfully out-licensed more than 10 clinical or near-clinical programs, further solidifying its leadership in the global biotechnology sector.
- Strategic Expansion: This listing will facilitate Biocytogen's global expansion and platform commercialization, leveraging the synergies of its “H+A” dual-listing structure to deepen collaborations with international partners and drive the discovery of novel therapies to benefit global healthcare.
See More
Biocytogen Lists on Shanghai STAR Market, Opens 117% Higher
- Listing Milestone: Biocytogen successfully listed on the Shanghai STAR Market with an IPO price of 26.68 RMB per share, opening at 58 RMB, which represents a 117% increase over the offering price and a market capitalization exceeding 25.9 billion RMB, marking its status as the first “H+A” dual-listed global drug innovator.
- Platform Advantage: The company leverages its RenMice® platforms to support the discovery of fully human monoclonal antibodies across over 1,000 druggable targets, having advanced more than 40 assets from PCC to IND stage, showcasing its leadership in antibody drug development.
- Global Collaborations: Biocytogen has established over 280 global discovery partnerships, including more than 10 successful out-licensing clinical or near-clinical programs, further solidifying its influence in the international market.
- Strategic Expansion: This listing will facilitate Biocytogen's global expansion and platform commercialization, leveraging the synergies of its “H+A” dual-listing structure to deepen collaborations with international partners and drive the discovery of novel therapies to benefit global healthcare.
See More
Biocytogen's Partner IDEAYA Receives FDA Clearance for Phase 1 Trial of IDE034
- Clinical Trial Approval: IDEAYA has received FDA clearance to initiate a Phase 1 clinical trial for IDE034, with patient enrollment expected to begin in Q1 2026, marking a significant milestone for Biocytogen in the development of bispecific antibody-drug conjugates (ADCs).
- Technical Validation: IDE034, a bispecific B7H3/PTK7 TOP1 ADC independently developed by Biocytogen, will drive subsequent clinical development following its licensing, showcasing Biocytogen's technical capabilities in bispecific ADC discovery and development.
- Anti-Tumor Activity: Preclinical studies have demonstrated that IDE034 monotherapy induces deep and durable tumor regressions in multiple B7H3/PTK7-positive tumor models, indicating its strong anti-tumor activity and potential to offer new therapeutic options for patients.
- Combination Strategy Exploration: IDEAYA plans to explore combination strategies with its PARG inhibitor IDE161 to enhance response durability and intends to present additional preclinical data supporting the combination rationale at a major medical conference in H1 2026.
See More
